Compositions and methods for treating cardiac injury
This invention is directed to compositions and methods for treating a condition of the heart. In an embodiment, the invention is directed to a method of treating a subject in need thereof, wherein the method comprises ablating at least one nerve of the renal artery of the subject; and administering to the subject a therapeutically effective amount of cells.
1. A method of treating a subject suffering from heart disease in need thereof, wherein the method comprises attenuating at least one nerve of the renal artery of the subject; and administering to the subject a therapeutically effective amount of cardiac-derived stem cells.
2. The method of claim 1 , wherein the method comprises attenuating the activity of the sympathetic nervous system of the subject.
3. The method of claim 2 , wherein attenuating comprises vagal nerve stimulation (VNS), spinal cord stimulation (SCS), baroreceptor stimulation, renal denervation, tragus stimulation, endovascular stimulation, endovascular cardiac plexus stimulation or a combination thereof.
4. The method of claim 2 , wherein attenuating is measured by microneurography, positron emission tomography (PET), heart rate, heart rate viability, heart rate recovery following exercise, baroreflex sensitivity, or a combination thereof.
5. The method of claim 1 , wherein the nerve comprises a sympathetic nerve.
6. The method of claim 1 , wherein attenuating at least one nerve of the renal artery comprises attenuation of at least one sympathetic nerve of the renal artery, wherein attenuation comprises ablation, radiofrequency denervation, ultrasound, chemical ablation, or a combination thereof.
7. The method of claim 1 , wherein the administering of the cells occurs prior to or subsequent to nerve attenuation.
8. The method of claim 1 , wherein the cells are administered intracoronarilly, intramyocardially, intravenously, intraarterially, or any combination thereof.
9. The method of claim 1 , wherein the cells are autologous cells, homologous cells, allogenic cells, heterologous cells, or any combination thereof.
10. The method of claim 1 , wherein the heart disease comprises a myocardial injury, myocardial infarction, heart failure, a congenital heart defect, a structural heart disease, an inflammation-mediated heart disease, hypertension-induced heart failure, or any combination thereof.
11. The method of claim 10 , wherein heart failure comprises heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF).
12. The method of claim 10 , wherein the heart failure is metabolic-syndrome induced, artificially induced from a composition administered to a subject, naturally occurring, or a combination thereof.
13. The method of claim 12 , wherein the composition comprises an anti-cancer agent.
14. The method of claim 1 , further comprising the step of measuring cardiac function of the subject.
15. The method of claim 14 , wherein the cardiac function comprises left ventricular ejection fraction, left ventricular diastolic function, or a combination thereof.
16. The method of claim 15 , wherein an increase in the left ventricular ejection fraction indicates an improved cardiac function.
17. The method of claim 14 , wherein the measuring comprises measuring a myocardial peptide marker, a circulating peptide marker, a heart pump function, a heart gross morphology, an enzymatic activity, or a combination thereof.
18. The method of claim 17 , wherein heart pump function is measured by echocardiogram.
19. The method of claim 1 , wherein myocardial injury results from heart failure, myocardial infarction, ischemia/reperfusion, or a combination thereof.
20. A method for improving cardiac function of a subject suffering from heart disease, the method comprising ablating at least one nerve of the renal artery; and administering to the subject a therapeutically effective amount of cardiac-derived stem cells.